These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16178762)

  • 21. Cartilage damage and bone erosion are more prominent determinants of functional impairment in longstanding experimental arthritis than synovial inflammation.
    Hayer S; Bauer G; Willburger M; Sinn K; Alasti F; Plasenzotti R; Shvets T; Niederreiter B; Aschauer C; Steiner G; Podesser BK; Smolen JS; Redlich K
    Dis Model Mech; 2016 Nov; 9(11):1329-1338. PubMed ID: 27638666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion.
    Lubberts E; Joosten LA; Chabaud M; van Den Bersselaar L; Oppers B; Coenen-De Roo CJ; Richards CD; Miossec P; van Den Berg WB
    J Clin Invest; 2000 Jun; 105(12):1697-710. PubMed ID: 10862785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of inflammatory bone erosion by constitutively active STAT-6 through blockade of JNK and NF-kappaB activation.
    Hirayama T; Dai S; Abbas S; Yamanaka Y; Abu-Amer Y
    Arthritis Rheum; 2005 Sep; 52(9):2719-29. PubMed ID: 16142755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system.
    Tanaka Y; Ohira T
    Curr Opin Pharmacol; 2018 Jun; 40():110-119. PubMed ID: 29702364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis.
    Pettit AR; Ji H; von Stechow D; Müller R; Goldring SR; Choi Y; Benoist C; Gravallese EM
    Am J Pathol; 2001 Nov; 159(5):1689-99. PubMed ID: 11696430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-kappaB-dependent, CD40-mediated bone destruction in rheumatoid arthritis.
    Lee HY; Jeon HS; Song EK; Han MK; Park SI; Lee SI; Yun HJ; Kim JR; Kim JS; Lee YC; Kim SI; Kim HR; Choi JY; Kang I; Kim HY; Yoo WH
    Arthritis Rheum; 2006 Jun; 54(6):1747-58. PubMed ID: 16736517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RANK-Independent Osteoclast Formation and Bone Erosion in Inflammatory Arthritis.
    O'Brien W; Fissel BM; Maeda Y; Yan J; Ge X; Gravallese EM; Aliprantis AO; Charles JF
    Arthritis Rheumatol; 2016 Dec; 68(12):2889-2900. PubMed ID: 27563728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.
    Binder NB; Puchner A; Niederreiter B; Hayer S; Leiss H; Blüml S; Kreindl R; Smolen JS; Redlich K
    Arthritis Rheum; 2013 Mar; 65(3):608-17. PubMed ID: 23280418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
    Dai SM; Nishioka K; Yudoh K
    Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
    van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI
    Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolactin blocks the expression of receptor activator of nuclear factor κB ligand and reduces osteoclastogenesis and bone loss in murine inflammatory arthritis.
    Ledesma-Colunga MG; Adán N; Ortiz G; Solís-Gutiérrez M; López-Barrera F; Martínez de la Escalera G; Clapp C
    Arthritis Res Ther; 2017 May; 19(1):93. PubMed ID: 28506283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mechanism of the bone destruction in rheumatoid arthritis].
    Nakamura M; Tanaka S
    Nihon Rinsho; 2005 Sep; 63(9):1571-3. PubMed ID: 16164213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo.
    Jimi E; Aoki K; Saito H; D'Acquisto F; May MJ; Nakamura I; Sudo T; Kojima T; Okamoto F; Fukushima H; Okabe K; Ohya K; Ghosh S
    Nat Med; 2004 Jun; 10(6):617-24. PubMed ID: 15156202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse.
    Mori H; Kitazawa R; Mizuki S; Nose M; Maeda S; Kitazawa S
    Histochem Cell Biol; 2002 Mar; 117(3):283-92. PubMed ID: 11914926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morphological characterization of receptor activator of NFkappaB ligand (RANKL) and IL-1beta expression in rodent collagen-induced arthritis.
    Weiss RJ; Erlandsson Harris H; Wick MC; Wretenberg P; Stark A; Palmblad K
    Scand J Immunol; 2005 Jul; 62(1):55-62. PubMed ID: 16092922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
    Haynes DR; Crotti TN; Loric M; Bain GI; Atkins GJ; Findlay DM
    Rheumatology (Oxford); 2001 Jun; 40(6):623-30. PubMed ID: 11426018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone changes in early rheumatoid arthritis.
    Green MJ; Deodhar AA
    Best Pract Res Clin Rheumatol; 2001 Mar; 15(1):105-23. PubMed ID: 11358418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
    Schett G; Middleton S; Bolon B; Stolina M; Brown H; Zhu L; Pretorius J; Zack DJ; Kostenuik P; Feige U
    Arthritis Rheum; 2005 May; 52(5):1604-11. PubMed ID: 15880601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.